Journal ArticleDOI
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era : evaluation of its impact within a subgroup of the randomized German CML Study IV
Susanne Saussele,Michael Lauseker,Alois Gratwohl,Dietrich W. Beelen,Donald Bunjes,Rainer Schwerdtfeger,Hans-Jochem Kolb,Anthony D. Ho,Christiane Falge,Ernst Holler,Günter Schlimok,Axel R. Zander,Renate Arnold,Lothar Kanz,Robert Dengler,Claudia Haferlach,Brigitte Schlegelberger,Markus Pfirrmann,Martin C. Müller,Susanne Schnittger,Armin Leitner,Nadine Pletsch,Andreas Hochhaus,Joerg Hasford,Rüdiger Hehlmann +24 more
TLDR
It is concluded that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor.About:
This article is published in Blood.The article was published on 2010-03-11. It has received 201 citations till now. The article focuses on the topics: Transplantation & Hematopoietic stem cell transplantation.read more
Citations
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Benjamin Hanfstein,Martin C. Müller,Rüdiger Hehlmann,Philipp Erben,Michael Lauseker,Alice Fabarius,Susanne Schnittger,Claudia Haferlach,Gudrun Göhring,Ulrike Proetel,Hans-Jochem Kolb,Stefan W. Krause,Wolf-K. Hofmann,J. Schubert,H. Einsele,Jolanta Dengler,Mathias Hänel,C. Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Susan Branford,Susan Branford,Timothy P. Hughes,Karsten Spiekermann,Gabriela M. Baerlocher,Markus Pfirrmann,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +32 more
TL;DR: Treatment optimization is recommended for pts missing these landmarks and early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise consider the use of a second-generation tyrosine kinase inhibitor (TKI).
Journal ArticleDOI
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Rüdiger Hehlmann,Michael Lauseker,Susanne Jung-Munkwitz,Armin Leitner,Martin Müller,Nadine Pletsch,Ulrike Proetel,Claudia Haferlach,Brigitte Schlegelberger,Leopold Balleisen,Mathias Hänel,Markus Pfirrmann,Stefan W. Krause,Christoph Nerl,Hans Pralle,Alois Gratwohl,Dieter K. Hossfeld,Joerg Hasford,Andreas Hochhaus,Susanne Saußele +19 more
TL;DR: Early high-dose therapy followed by rapid adaptation to good tolerability increases the rate of major molecular remission (MMR) at 12 months, and achievement of MMR by month 12 is directly associated with improved survival.
Journal ArticleDOI
Chronic Myeloid Leukaemia
TL;DR: This Seminar summarises the presentation, pathophysiology, diagnosis and monitoring technology, treatment options, side-effects, and outcomes of chronic myeloid leukaemia, and discusses the possibility of cure-ie, stable undetectable or low level disease in the absence of medication.
Journal ArticleDOI
Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV
Rüdiger Hehlmann,Martin C. Müller,Michael Lauseker,Benjamin Hanfstein,Alice Fabarius,Annette Schreiber,Ulrike Proetel,Nadine Pletsch,Markus Pfirrmann,Claudia Haferlach,Susanne Schnittger,H. Einsele,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Gerhard Ehninger,Dominik Heim,Hermann Heimpel,Christoph Nerl,Stefan W. Krause,Dieter K. Hossfeld,Hans-Jochem Kolb,Joerg Hasford,Susanne Saußele,Andreas Hochhaus +31 more
TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.
References
More filters
Journal ArticleDOI
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators
Ted Gooley,Ted Gooley,Wendy M. Leisenring,Wendy M. Leisenring,John Crowley,John Crowley,Barry E. Storer,Barry E. Storer +7 more
TL;DR: A representation of each estimate in a manner not ordinarily seen is presented, each representation utilizing the concept of censored observations being 'redistributed to the right' to allow a more intuitive understanding of each estimates.
Journal ArticleDOI
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani,Giuseppe Saglio,John M. Goldman,Andreas Hochhaus,Bengt Simonsson,Frederick R. Appelbaum,Jane F. Apperley,Francisco Cervantes,Jorge E. Cortes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Dietger Niederwieser,Richard T. Silver,Rüdiger Hehlmann +18 more
Journal ArticleDOI
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P. Hughes,Michael W. Deininger,Andreas Hochhaus,Susan Branford,Jerald P. Radich,Jaspal Kaeda,Michele Baccarani,Jorge E. Cortes,Nicholas C.P. Cross,Brian J. Druker,Jean Gabert,David Grimwade,Rüdiger Hehlmann,Suzanne Kamel-Reid,Jeffrey H. Lipton,Janina A. Longtine,Giovanni Martinelli,Giuseppe Saglio,Simona Soverini,Wendy Stock,John M. Goldman +20 more
TL;DR: Suggestions are made for harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR -ABL transcript levels on an internationally agreed scale.
Journal ArticleDOI
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Joseph E. Sokal,EB Cox,Michele Baccarani,Tura S,German A. Gomez,Judith E. Robertson,CY Tso,Thomas J. Braun,Bayard D. Clarkson,Francisco Cervantes +9 more
TL;DR: The prognostic significance of disease features recorded at the time of diagnosis was examined among 813 patients with Philadelphia chromosome- positive, nonblastic chronic granulocytic leukemia (CGL) collected from six European and American series, and it should be possible to identify a lower risk group of patients with a 2-yr survival of 90%, subsequent risk averaging somewhat less than 20%/yr and median survival of 5 yr.
Journal ArticleDOI
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
Joerg Hasford,Markus Pfirrmann,Rüdiger Hehlmann,N. C. Allan,Michele Baccarani,J. C. Kluin-Nelemans,Guiliana Alimena,Juan Luis Steegmann,H. Ansari +8 more
TL;DR: A new prognostic scoring system for estimating survival of patients with CML treated with interferon alfa has been developed and validated through use of a large dataset and the ability of the new scoring system to discriminate risk groups was confirmed.
Related Papers (5)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani,Jorge E. Cortes,Fabrizio Pane,Dietger Niederwieser,Giuseppe Saglio,Jane F. Apperley,Francisco Cervantes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Andreas Hochhaus,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Jerald P. Radich,Bengt Simonsson,Richard T. Silver,John M. Goldman,Rüdiger Hehlmann +19 more
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Hagop M. Kantarjian,Neil P. Shah,Andreas Hochhaus,Jorge E. Cortes,Sandip Shah,Manuel Ayala,Beatriz Moiraghi,Zhixiang Shen,Jiri Mayer,Ricardo Pasquini,Hirohisa Nakamae,Françoise Huguet,Concepción Boqué,Charles Chuah,Eric Bleickardt,M. Brigid Bradley-Garelik,Chao Zhu,Ted Szatrowski,David Shapiro,Michele Baccarani +19 more
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more